Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$4.41 -2.4%	$3.93	$3.21 ▼ $7.18	$1.08B	0.6	4.41 million shs	3.25 million shs
COGT Cogent Biosciences	$12.49 +2.4%	$7.22	$3.72 ▼ $12.94	$1.39B	1.88	1.63 million shs	3.68 million shs
KURA Kura Oncology	$6.36 -3.6%	$6.11	$5.41 ▼ $21.65	$571.39M	0.4	1.29 million shs	1.06 million shs
RNA Avidity Biosciences	$33.76 -0.8%	$30.98	$21.51 ▼ $56.00	$4.10B	0.91	1.42 million shs	2.72 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-1.74%	-3.83%	+27.32%	-6.22%	-21.39%
COGT Cogent Biosciences	+2.87%	+12.44%	+60.10%	+179.18%	+35.86%
KURA Kura Oncology	+3.45%	+3.77%	+6.45%	+11.86%	-69.63%
RNA Avidity Biosciences	+1.52%	+8.17%	+15.94%	+27.68%	-24.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.1578 of 5 stars	3.5	1.0	4.4	3.0	2.5	0.6
COGT Cogent Biosciences	3.5461 of 5 stars	4.4	3.0	0.0	2.8	1.7	0.6
KURA Kura Oncology	4.565 of 5 stars	4.4	2.0	4.7	3.5	0.8	0.6
RNA Avidity Biosciences	2.1866 of 5 stars	4.5	0.0	0.0	2.7	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$10.89	146.91% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	49.72% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	285.22% Upside
RNA Avidity Biosciences	3.06	Buy	$66.35	96.54% Upside

Current Analyst Ratings Breakdown

Latest RNA, COGT, KURA, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
7/7/2025	COGT Cogent Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $28.00
7/7/2025	COGT Cogent Biosciences	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	3.16	N/A	N/A	$0.73 per share	6.04
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
KURA Kura Oncology	$53.88M	10.22	N/A	N/A	$5.32 per share	1.20
RNA Avidity Biosciences	$10.90M	373.28	N/A	N/A	$11.94 per share	2.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	14.23	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest RNA, COGT, KURA, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	KURA Kura Oncology	$0.15	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	RNA Avidity Biosciences	-$0.93	N/A	N/A	N/A	$1.61 million	N/A
8/7/2025	Q2 2025	ARDX Ardelyx	-$0.12	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.54	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.04	4.12	3.81
COGT Cogent Biosciences	N/A	5.13	5.13
KURA Kura Oncology	0.02	8.07	8.07
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
COGT Cogent Biosciences	N/A
KURA Kura Oncology	N/A
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
COGT Cogent Biosciences	7.29%
KURA Kura Oncology	6.40%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

RNA, COGT, KURA, and ARDX Headlines

Recent News About These Companies

Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive

July 14, 2025 | seekingalpha.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's Why

July 14, 2025 | marketbeat.com

Avidity Biosciences price target raised to $70 from $60 at Evercore ISI

July 12, 2025 | msn.com

Alps Advisors Inc. Has $2.58 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 12, 2025 | marketbeat.com

The Goldman Sachs Group Upgrades Avidity Biosciences (NASDAQ:RNA) to Buy

July 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Balance Sheet - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 6, 2025 | marketbeat.com

Avidity Biosciences, Inc. (RNA) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

7RNA : Expert Outlook: Avidity Biosciences Through The Eyes...

June 27, 2025 | benzinga.com

Avidity Biosciences (NASDAQ:RNA) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA therapies stock faces pivotal year

June 26, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Analysts

June 26, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. Bernstein

June 24, 2025 | marketbeat.com

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

June 24, 2025 | investing.com

SG Americas Securities LLC Takes $516,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 23, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027

June 20, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in Stock

June 19, 2025 | insidertrades.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 Shares

June 18, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential

June 16, 2025 | investing.com

Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation

June 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
3 Catalysts Driving Plug Power’s Turnaround Case
By Jeffrey Neal Johnson | July 18, 2025
View 3 Catalysts Driving Plug Power’s Turnaround Case

RNA, COGT, KURA, and ARDX Company Descriptions

Ardelyx NASDAQ:ARDX

$4.41 -0.11 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$4.39 -0.02 (-0.45%)

As of 07:55 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Cogent Biosciences NASDAQ:COGT

$12.49 +0.29 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$12.48 -0.01 (-0.08%)

As of 07:56 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Kura Oncology NASDAQ:KURA

$6.36 -0.24 (-3.64%)

Closing price 04:00 PM Eastern

Extended Trading

$6.43 +0.07 (+1.12%)

As of 07:57 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Avidity Biosciences NASDAQ:RNA

$33.76 -0.28 (-0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$33.95 +0.19 (+0.56%)

As of 07:07 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time